10 steps for a successful global economic model

Jul 25, 2022

Written by Beth Hancock, Senior Consultant Health Economist

Pharmaceutical companies often develop global cost-effectiveness and budget impact models, with the aim of adapting them for specific countries. In principle, this is an efficient and streamlined process, but the challenge of developing a single model for diverse healthcare systems and health technology assessment (HTA) processes means that it’s rarely straightforward.

Those familiar with the development of global models might recognise the following pitfalls:

  • Sharing a finalised global model with participating countries, only to find that a further change is required after adaptations have already begun
  • Learning that a key comparator for a subset of countries has not been included when the global model is close to finalisation
  • Including a complex modelling component to meet the needs of a specific country that is a hindrance to other countries and is difficult to remove without breaking the model
  • A country is close to submission and wishes to know the feedback from other HTA bodies on a key model uncertainty, but a centralised repository of feedback from completed and ongoing HTA appraisals does not exist.

Successful global models, on the other hand, minimise the time, effort, and resource required across both the participating countries and the global team, and give each country a strong starting position for reimbursement success. But how can this be done?

The team at Source Health Economics has developed global economic models across cardiovascular disease, oncology, muscular dystrophy, liver disease, haemophilia, retinal conditions, and skin conditions. In the process, we have established a set of guiding principles to develop a successful global model (provided in the table below). You will note that some of these principles apply to the development of all models, but the impact of errors or mis-steps is amplified in a model distributed globally. As we continue to work with our clients on the development of these models, we expect this list to grow, adapt, and evolve as we face new challenges and identify new solutions – but for now, we hope you find this useful.

If you would like to learn more about global economic models or discuss a current challenge, please contact us at Source Health Economics, an independent consultancy specialising in evidence generation, health economics, and communication.


More Insights

NICE refines the HST routing criteria: What you need to know

NICE refines the HST routing criteria: What you need to know

Written by Brian O'Toole   The National Institute for Health and Care Excellence (NICE) Highly Specialised Technologies (HST) programme is designed to evaluate innovative treatments for rare and complex conditions. On 19th March ... Read more

Systematic review case study: scoping research to identify comparators

Systematic review case study: scoping research to identify comparators

Written by Sneha Bhadti and David Pritchett   Establishing a list of relevant comparators at the protocol development stage is a vital step in the systematic literature review (SLR) process. Scoping research during this stage can help ... Read more

National Numeracy Day 2025: Why money and maths matter in health economics

National Numeracy Day 2025: Why money and maths matter in health economics

Written by Abby Paine and Dom Partridge This is our third year celebrating National Numeracy Day, and this year’s theme of money is especially relevant for those of us working in health economics and market access. In previous years, ... Read more

Maximising SLRs for HEOR – why PICO matters

Maximising SLRs for HEOR – why PICO matters

Written by Susan O’Connell and Sara Bartlome   Introduction Systematic literature reviews (SLRs) seek to answer a specific research question by translating the question into search terms and developing a literature search strategy to ... Read more